NEWTOWN, Pa., June 3 /PRNewswire/ -- CollaGenex Pharmaceuticals, Inc.
(Nasdaq: CGPI) announced today the hiring of Douglas C. Gehrig as Vice
President, Sales and David F. Pfeiffer as Vice President, Marketing.
    Mr. Gehrig brings to CollaGenex more than two decades of sales management
experience at companies including McNeil Pharmaceuticals, Johnson and Johnson
Oral Care and Warner Lambert Consumer Products.  Most recently, he was Vice
President in charge of sales and marketing for the Musculoskeletal Transplant
Foundation, the market leader in providing human allograft material for use in
orthopaedic, neuro and periodontal surgery.  He holds a B.S. from the
University of Nebraska.
    Mr. Pfeiffer has pharmaceutical sales and marketing experience with
American Cyanamid, Zeneca Pharmaceutical Group, Stuart Disease Management
Services and, most recently, SmithKline Beecham, where he was responsible for
the development of disease management programs.  He holds a B.S. from Rutgers
University and an M.B.A. from the Kellogg School of Management of Northwestern
University.
    "We are very pleased to add these two highly experienced sales and
marketing executives to our team as the next step in executing our strategy,"
said Brian M. Gallagher, Ph.D., President and Chief Executive Officer of
CollaGenex.  "Their mix of experience in the pharmaceutical, dental, consumer
product and disease management fields provides an unusually strong platform
from which to broaden our commercial expansion."
    CollaGenex recently announced the launch of its dedicated contract sales
force, which will promote Ponstel, a Parke-Davis drug for relief of moderate
pain, to the professional dental community.  The company also expects Food and
Drug Administration approval of Periostat, a novel and proprietary
pharmaceutical therapy for periodontal disease.  The Periostat New Drug
Application was submitted to the FDA in August 1996.
    CollaGenex Pharmaceuticals is an emerging pharmaceutical company which is
developing and commercializing innovative proprietary medical therapies for
the treatment of periodontal disease and other pathologies.  The company's
core technology involves inhibiting the activity of certain enzymes that
destroy the connective tissues of the body.  In addition to periodontal
disease, the company and its collaborators are researching and developing
other potential applications of the core technology, including cancer
metastasis, wound healing, osteoarthritis, osteoporosis, rheumatoid arthritis
and diabetic complications.  Founded in 1992, the company completed an initial
public offering of two million shares of common stock in June 1996.
    To receive additional information on CollaGenex, via fax, at no charge,
dial 1-800-PRO-INFO and enter code CGPI.

    This news release contains forward-looking statements and therefore it
necessarily involves risks and uncertainties.  Factors that could cause actual
events to differ from these forward-looking statements are set forth under the
caption "Risk Factors" in the company's prospectus dated June 20, 1996, which
is part of its registration statement on file with the Securities and Exchange
Commission.  There can be no assurance that the company will receive
regulatory approval to market any product or, if such approval is received,
that the product will be commercially successful.

Link to this page: